1. P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study. (27th May 2021) Authors: Mocci, G; Cuomo, A; Allegretta, L; Aragona, G; Colucci, R; Della Valle, N; Ferronato, A; Forti, G; Gaiani, F; Graziani, M G; Lorenzetti, R; Luzza, F; Penna, A; Pica, R; Piergallini, S; Rodinò, S; Scarcelli, A; Zampaletta, C; Cicerone, C; Cocco, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn's disease: results from "long vedo" italian multicenter study. (30th January 2023) Authors: Mocci, G; Maconi, G; Onidi, F M; Cataletti, G; Elisei, W; Scaldaferri, F; Lorenzetti, R; Pagnini, C; Scarcelli, A; Graziani, M G; Di Paolo, M C; Pranzo, G; Luppino, I; Monterubbianesi, R; Faggiani, R; Ferronato, A; Savarino, E; Pica, R; Cocco, A; Rodino, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗